Cytori Therapeutics (CYTX) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Capital Cuts Price Target on Cytori Therapeutics (CYTX) Following 2Q Earnings Report
August 10, 2015 7:56 AM EDTRoth Capital reiterated a Buy rating on Cytori Therapeutics, Inc. (NASDAQ: CYTX), and cut the price target to $4.00 (from $6.00), following the company's 2Q15 earnings release. EPS of $0.03 beat the consensus estimates of -$0.03. CYTX ended the quarter with $23.8 million in cash.
Analyst Joseph Pantginis... More
Cytori Therapeutics (CYTX) PT Trimmed to $5 at Maxim Group; 'Buy' Maintained
August 7, 2015 7:43 AM EDTMaxim Group analyst Jason Kolbert trimmed his price target on Cytori Therapeutics, Inc. (NASDAQ: CYTX) to $5.00 (from $7.00) following Q2 results but maintained his Buy rating.
The cut comes on a greater than expected share count.
The analyst highlighted the following Quarter Progress: STAR TRIAL, OA, Incontinence and Burns
Announced the launch of its US STAR trial, which is being considered a "pivotal"... More